Video
Dr. Ferris on FDA Approval of Pembrolizumab in Head and Neck Cancer
Author(s):
Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the impact of the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with head and neck cancer.
Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the impact of the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with head and neck cancer.
Latest CME
View All
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina
May 2nd 2025 - Jun 7th 2025
Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas
May 1st 2025 - Jun 6th 2025
From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment
May 1st 2025 - May 2nd 2026
.png?fit=crop&auto=format)
